Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-2843 in relapsed/refractory acute leukemias
NCT04872478Phase 1Recruiting
- Sponsor
- Meryx, Inc.
- Start
- Apr 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MRX-2843 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (6 arms), sponsored by Meryx, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events up to 8 months. Started Apr 2022; status: recruiting.
02
Drugs
MRX-2843
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04872478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872478.